David R. Nelson

24.3k total citations · 7 hit papers
266 papers, 14.0k citations indexed

About

David R. Nelson is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, David R. Nelson has authored 266 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 186 papers in Hepatology, 140 papers in Epidemiology and 31 papers in Infectious Diseases. Recurrent topics in David R. Nelson's work include Hepatitis C virus research (171 papers), Liver Disease Diagnosis and Treatment (112 papers) and Hepatitis B Virus Studies (73 papers). David R. Nelson is often cited by papers focused on Hepatitis C virus research (171 papers), Liver Disease Diagnosis and Treatment (112 papers) and Hepatitis B Virus Studies (73 papers). David R. Nelson collaborates with scholars based in United States, Germany and France. David R. Nelson's co-authors include Roniel Cabrera, Chen Liu, Roberto J. Firpi, Michael Fried, Gary L. Davis, Mark Sulkowski, Doris B. Strader, Marc G. Ghany, Leonard B. Seeff and David L. Thomas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Physical Review Letters.

In The Last Decade

David R. Nelson

259 papers receiving 13.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

2011 828 citations David R. Nelson et al. Hepatology profile →
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 686 citations David R. Nelson, Dorothy H. Crawford et al. profile →
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

2011 566 citations David R. Nelson, Mark Sulkowski et al. profile →
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection

2017 504 citations David R. Nelson, Michael Fried et al. profile →
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

2015 477 citations David R. Nelson, Tarek Hassanein et al. profile →
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

2017 271 citations David R. Nelson et al. profile →
The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C

1997 270 citations David R. Nelson, Gary L. Davis et al. The Journal of Immunology profile →

Peers

David R. Nelson

HEPAT

EPIDE

IMMUN

Francesco Negro Switzerland

Masahiro Kobayashi Japan

Marc G. Ghany United States

Stanislas Pol France

Geoffrey Dusheiko United Kingdom

Ira M. Jacobson United States

Myron J. Tong United States

Mark Thursz United Kingdom

Edward Gane New Zealand

Robert G. Gish United States

Francesco Negro Switzerland

David R. Nelson

12.4k ×1.2

HEPAT

12.2k ×1.4

EPIDE

1.5k ×0.9

833 ×0.6

IMMUN

1.4k ×1.3

Citations per year, relative to David R. Nelson David R. Nelson (= 1×) peers Francesco Negro

Countries citing papers authored by David R. Nelson

Since Specialization

Citations

This map shows the geographic impact of David R. Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Nelson more than expected).

Fields of papers citing papers by David R. Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Nelson. The network helps show where David R. Nelson may publish in the future.

Co-authorship network of co-authors of David R. Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Nelson. A scholar is included among the top collaborators of David R. Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Nelson. David R. Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nelson, David R., et al.. (2025). The humor paradox and identity in professional stand-up comedy: humor enactment as a predictor of personal-relational and enacted-relational identity gaps in the comedian–audience relationship. Communication Research Reports. 42(2). 116–127.

Bae, Jay, Lee Kallenbach, David R. Nelson, et al.. (2024). Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry. BMC Endocrine Disorders. 24(1). 59–59. 4 indexed citations

Lok, Anna S., Mark Sulkowski, Jens Kort, et al.. (2019). Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 157(6). 1506–1517.e1. 34 indexed citations

Nelson, David R., et al.. (2016). Evaluating Podcast Compositions: Assessing Credibility, Challenges, and Innovation. Social Media + Society. 5(1). 38–64. 7 indexed citations

Welzel, Tania M., David R. Nelson, Giuseppe Morelli, et al.. (2016). Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 66(10). 1844–1852. 61 indexed citations

Morelli, Giuseppe, Roberto J. Firpi, Joy Peter, et al.. (2015). Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination with Sofosbuvir in Naive Subjects with HCV Genotype 1 Short Title: Telaprevir & Sofosbuvir in HCV Genotype 1. Journal of Gastroenterology and Hepatology Research. 4(5). 1599–1604. 2 indexed citations

Morelli, Giuseppe, Roberto J. Firpi, Lucy Akushevich, et al.. (2015). Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination With Sofosbuvir in Naive Subjects Infected With Hepatitis C Virus Genotype 1. Journal of Gastroenterology and Hepatology Research. 4(5). 1599–1604. 1 indexed citations

Nelson, David R., K. Rajender Reddy, Adrian M. Di Bisceglie, et al.. (2014). ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials. Hepatology. 60. 5 indexed citations

Nelson, David R., Pietro Andreoné, M. Colombo, et al.. (2014). HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon. Hepatology. 60. 1 indexed citations

10.

Clark, Virginia, Renumathy Dhanasekaran, C. Soldevila‐Pico, et al.. (2011). 537 A SUSTAINED VIRAL RESPONSE DRAMATICALLY IMPROVES SURVIVAL IN PATIENTS WITH HEPATITIS C INFECTION AFTER LIVER TRANSPLANT. Journal of Hepatology. 54. S219–S220. 1 indexed citations

11.

Nowakowski, Christopher, et al.. (2011). Cooperative Adaptive Cruise Control: Testing Drivers' Choices of Following Distances. RePEc: Research Papers in Economics. 51 indexed citations

12.

Tran, Thanh-Hai, E. Howington‐Kraus, B. A. Archinal, et al.. (2010). Generating Digital Terrain Models from LROC stereo images with Socet Set. elib (German Aerospace Center). 2515. 15 indexed citations

13.

Cabrera, Roniel & David R. Nelson. (2009). Review article: the management of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics. 31(4). 461–476. 198 indexed citations

14.

Nelson, David R., Gary L. Davis, Ira M. Jacobson, et al.. (2008). Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy. Clinical Gastroenterology and Hepatology. 7(4). 397–414. 11 indexed citations

15.

Cao, Mengde, Yiling Xu, Roniel Cabrera, Chen Liu, & David R. Nelson. (2007). Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells (88.2). The Journal of Immunology. 178(1_Supplement). S138–S138. 4 indexed citations

16.

Balan, Vijayan, David R. Nelson, Mark Sulkowski, et al.. (2006). Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.. PubMed. 11(7). 901–8. 12 indexed citations

17.

Shladover, Steven E, Xiao‐Yun Lu, Bongsob Song, et al.. (2006). Demonstration of Automated Heavy-Duty Vehicles. eScholarship (California Digital Library). 7 indexed citations

18.

Zhu, Haizhen, David R. Nelson, James M. Crawford, & Chen Liu. (2005). Defective Jak-Stat Activation in Hepatoma Cells Is Associated with Hepatitis C Viral IFN-α Resistance. Journal of Interferon & Cytokine Research. 25(9). 528–539. 43 indexed citations

19.

Reed, Alan, Richard J. Howard, Shiro Fujita, et al.. (2005). Liver Retransplantation: A Single-Center Outcome and Financial Analysis. Transplantation Proceedings. 37(2). 1161–1163. 29 indexed citations

20.

Nelson, David R., et al.. (1986). Differentiation and secretory activities of cultured human placental cytotrophoblast. Placenta. 7(1). 1–16. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact